吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效评价

目的探讨吉西他滨联合奈达铂治疗晚期非小细胞肺癌的临床疗效。方法72例晚期非小细胞肺癌患者随机分为奈达铂组38例，顺铂组34例。奈达铂组：奈达铂组40nag加入0．9％氯化钠溶液500mL，静滴2小时，第1～3天。顺铂组40mg加入0．9％氯化钠溶液500mL，静滴2小时，第1～3天；两组中吉西他滨800mg／m2，第1、8天。溶于0．9％氯化钠溶液100mL，静滴0．5h。2周期化疗后评估疗效及不良反应。结果奈达铂组总有效率为34．2％，顺铂组总有效率为34．6％，两组比较差异无显著性（P〉0．05）。奈达铂组血液学毒性较顺铂组严重，而消化道反应则较顺铂组轻。结论奈达铂联合吉西他滨与顺铂联合吉西他滨对晚期非小细胞肺癌临床疗效相当，奈达铂的消化道反应明显低于顺铂。

Clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer

Objective To explore clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods Seventy-two advanced NSCLC patients were randomly divided into nedaplatin group （n = 38） and cisplatin group （n = 34）. The nedaplatin group received treatment as follows： 40 mg, 0.9% sodium chloride solution 500 mL, Ⅳ drop 2 hours, d1 - 3. The cisplatin group： 40 mg add 0.9 % sodium chloride solution 500 mL, static drop 2 hours, d13. Gemcitabine 800 mg/m2 was administered in both groups, at dl and d8, 0.9% sodium chloride solution 100 mL, Ⅳ drop 2 hours. Curative effect and adverse events 2 weeks after chemotherapy were evaluted. Results Total effective rate was 34.2 % in the nedaplatin group, and 34.6 % in the cisplatin group. There were no significant differences. Conclu- sion Gemcitabine combined with nedaplatin has similar efficacy with that of gemcitabine combined with cisplatin in the treatment of advanced NSCLC. There are less adverse intestinal reactions caused by nedaplatin.